PMCB has missed it's golden opportunity to be the innovator. It is now far behind and chasing lower cost proven technology.
Beat to Market! Erytech is encapsulating therapeutic drug substances inside red blood cells. This eliminates PMCB's MCB issue, as patients bank their own blood. See for yourself the full data from its Phase 2b study evaluating it's technology for the treatment of metastatic pancreatic cancer. PMCB has no partner. PMCB is broke butt broke, and can't give away it's shelf offer. Erytech has TEVA backing, and was award granted 40mil + other grants. What Universities are PMCB partnered with? None = Red Flag. Longs think the Holy Grail is the submission of the IND. A Ham sandwich can submit an IND. Don't be fooled ... the Holy Grail is marketing approval, which comes after a successful 2b.
After THREE plus years of 2b clinicals, Erytech's 2b trials were successful, Marketing approval has been applied for, the technology patent is defendable, and the USA IPO is coming.
Do your DD, and drop the ZERO and get with a HERO!
Market Data 
Markets 
AI
